MedTrace Logo

An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications

NCT02678676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3599

Last updated 2016-07-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to investigate the mortality and macrovascular morbidity as well as the incidence of malignancies over time, in high-risk diabetic participants who previously received long-term treatment with either pioglitazone or placebo in combination with their usual medication for glycaemic management.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

OTHER

No Intervention

Participants who previously received Pioglitazone in the PROactive study (NCT00174993).

OTHER

No Intervention

Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
36 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2011-11-30
Completion
2011-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02678676 on ClinicalTrials.gov